Insulin Receptor in Aplysia Neurons: Characterization, Molecular Cloning, and Modulation of Ion Currents

Total Page:16

File Type:pdf, Size:1020Kb

Insulin Receptor in Aplysia Neurons: Characterization, Molecular Cloning, and Modulation of Ion Currents The Journal of Neuroscience, March 1, 1996, 76(5):1645-1658 Insulin Receptor in Aplysia Neurons: Characterization, Molecular Cloning, and Modulation of Ion Currents Elizabeth A. Jonas,2,a Ronald J. Knox,2 Leonard K. Kaczmarek,p James H. Schwat-tz,l and David H. Solomonl,” ‘Center for Neurobiology and Behavior, Columbia University College of Physicians and Surgeons, New York, New York 10032, and 2Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520 We have isolated the cDNA for a tyrosine kinase receptor that can be detected within 15-30 min. These effects were not seen is expressed in the nervous system of Aplysia californica and with insulin-like growth factor-l. In voltage-clamped neurons, that is similar to the vertebrate insulin receptor. Binding studies insulin produces an increase in the amplitude of the voltage- and immunocytochemical staining show that the receptor is dependent Ca2+ current that can be blocked by preincubation abundant in the bag cell neurons. Application of vertebrate with herbimycin A, an inhibitor of tyrosine kinases. Insulin also insulin to clusters of bag cell neurons stimulates the phosphor- enhances a delayed K’ current. We suggest that insulin-like ylation of the receptor on tyrosine residues, and exposure of peptides regulate the excitability of the bag cell neurons. isolated bag cell neurons to insulin produces an increase in Key words: insulin receptor; bag cell neurons; tyrosine kinase; height and a decrease in duration of the action potentials that Aplysia; calcium channels; potassium channels Insulin is a peptide growth factor that stimulates growth and (Schwartz et al., 1992),suggesting that insulin may act through the differentiation of various kinds of developing cells. For many blood streamas a hormone.In addition, insulincan be synthesized growth factors, the mechanismof transductioninvolves binding of by neurons and is releasedby depolarization, suggestingthat it the peptide to a membrane-spanningreceptor activating a ty- may act as a neurotransmitter or as a local peptide hormone rosine kinase in the cytoplasmicdomain of the receptor (Rosen, (Uvnas-Wallenstein,1981; Boyd et al., 1985).Several electrophys- 1987; Cantley et al., 1991). Many receptor and nonreceptor ty- iological actions of insulin have been described, including in- rosine kinasesare expressedabundantly in the mature nervous creasedelectrical coupling betweencultured sympatheticneurons system(Lai and Lemke, 1991), and their functions in long-term (Wolinsky et al., 1985) and inhibition of spontaneousfiring of rat programs of cell growth and differentiation are well described hippocampalneurons (Palovcik et al., 1984).Moreover, identified (Schlessingerand Ullrich, 1992). In neurons,changes induced by Aplysia neurons are rapidly hyperpolarized in responseto verte- protein tyrosine kinasesinfluence clustering of receptors during brate insulin (Shapiro et al., 1991). development (Huganir and Greengard, 1990) and extension of Insulin-like peptides have also been describedin nervous sys- axonal growth cones (Goldberg and Burmeister, 1992; Maness tems of many invertebrates (Thorpe and Duve, 1984; Steiner et and Cox, 1992). It is unclear, however, whether receptor tyrosine al., 1985), notably in the pond snail, Lymnaea stagnalis. These kinasesparticipate in short-term changesof neuronal excitability. molluscaninsulin-like peptides (MIPS) are similar in sequenceto Nevertheless,recent evidence suggeststhat tyrosine kinasesreg- mammalianinsulin and are believed to regulate reproduction and ulate ion channelsacutely (Huang et al., 1993;Wilson and Kacz- growth (Smit et al., 1988, 1991). Immunocytochemicalevidence marek, 1993; Wang and Salter, 1994) and that nonreceptor ty- indicates that many neurons in the central nervous systemsof rosine protein kinases are needed to induce long-term Lymnaea and Aplysia contain these peptides (Van Minnen and potentiation (O’Dell et al., 1991) and spatial learning (Grant et Schallig, 1990). al., 1992). We report the cDNA cloning and biochemicalcharacterization Whether insulin and insulin-like peptidesact in synaptic trans- of an insulin receptor from Aplysia califomica and show that it is missionis still uncertain. Havrankova et al. (1978) and Baskin et expressedabundantly in the bag cell neurons,a group of cellsthat al. (1987) detected receptors for insulin in mature vertebrate play a key role in the onset of reproductive behaviors(Conn and brain. An uptake mechanismfrom plasma has been described Kaczmarek, 1989). We also provide functional evidence that bag cell neuronsexpress a receptor similar to the mammalianinsulin Received Nov. 11, 1995; revised Dec. 7, 1995; accepted Dec. 8, 1995. receptor. Exposure of bag cell neurons to mammalianinsulin This work was supported by National Institutes of Health Grants NS29809 (J.H.S.), NS18492 (L.K.K.), and AGO0486 (E.A.J.), and by Research Scientist Award triggers autophosphorylationon tyrosine residuesof the bag cell MH00921 (J.H.S.). D.H.S. was supported by a Medical Research Council of Canada neuron receptor and enhancesvoltage-dependent Ca2+ and K+ Fellowship. We thank Alice Elste for her excellent technical assistance, John Koester currents, leading to changesin action potentials. for reading this manuscript, and Ken Kirschner for preparing this manuscript. Correspondence should be addressed to Dr. James H. Schwartz, Center for Neurobiology and Behavior, Columbia University College of Physicians and Sur- MATERIALS AND METHODS geons, 722 West 168th Street, New York, NY 10032. aE.A.J. and D.H.S. contributed equally to the work. Immunocytochemistry. Anti-peptide antibodies against the insulin-binding Dr. Solomon’s current address: Department of Pharmacology, Columbia Univer- pocket of the human insulin receptor 01 subunit (UBI, Lake Placid, NY) sity College of Physicians and Surgeons, 630 West 168th Street, New York, NY were diluted 1:20 for immunocytochemistry and 1:200 for immunoblot 10032. analysis. Tissues were fixed in Bouin’s fixative modified for Aplysia [2% Copyright 0 1996 Society for Neuroscience 0270-6474/96/161645-14$05.00/O paraformaldehyde, 15% picric acid, 1% glacial acetic acid in 0.1 M sodium 1646 J. Neurosci., March 1, 1996, 76(5):1645-1658 Jonas et al. l Insulin Receptor in Bag Cell Neurons phosphate, pH 7.4, containing 30% (w/v) sucrose]. Cryostat serial sections for 10 min at 16°C. The clusters were then homogenized in 400 ~1 of (10 pm) were mounted on gelatin-coated glass slides, rinsed with PBS buffer (1% Lubrol, 50 mM Tris-HCI, pH 7.4, 10 FM Na-orthovanadate, 30 containing 0.25% saponin, dehydrated and bleached in 0.3% H,O,, and mM Na-pyrophosphate, 50 mM NaF, 20 pM ZnCl,, 0.25 mM PMSF, and 10 then rehydrated. Sections were blocked with 2% normal goat serum and pg/ml each of leupeptin, antipain, pepstatin, and aprotinin) in glass-glass incubated in a 1:20 dilution of rabbit anti-insulin receptor antibody (150 tissue grinders for 3 min on ice. &ml) overnight at 4°C. Controls used were normal rabbit IgG (150 or 36 Samples were then centrifuged at 100,000 X g for 30 min. The super- &ml). Slides were rinsed again in PBS/saponin, incubated in rhodamine- natants were collected and transferred to I .5 ml Eppendorf tubes. Tubes conjugated goat anti-rabbit IgG, and rinsed and coverslipped with Aqua- were incubated at 4°C with rotation for 2 hr after addition of 1 pg of PolyMount (Polysciences, Warrington, PA). Sections were viewed by anti-insulin receptor p subunit monoclonal antibody (AB-3, Oncogene phase microscopy and epifluorescence with a Leitz microscope (filter Science, Manhasset, NY). After 20 ~1 protein G-Sepharose beads [50% pack N-2) and photographed with high-speed Kodak Tri-X film (Ro- (v/v) in lysis buffer; Pharmacia, Piscataway, NJ] were added and the chester, NY). samples were rotated at 4°C for 2 hr, the immunoprecipitates were Intact bag cell clusters and bag cell neurons in culture were examined collected by centrifugation at 3000 X g for 1 min and washed twice in 500 with a Bio-Rad MRC 1000 confocal apparatus (Bio-Rad, Cupertino, CA). ~1 of homogenization buffer, once in 500 ~1 of wash buffer (100 mM NaCI, Immunocytochemistry was performed as described above. Images were 50 mM Tris-HCI, pH 7.4, and 10 pM Na-orthovanadate), and once in 500 processed with Bio-Rad’s COMOS software package; 1.0 pm slices in the ~1 of kinase reaction mix (5 mM MnCI,, 5 mM MgCI,, 10 mM Tris-HCl, pH z-axis were processed and analyzed. 7.4, and 10 WM Na-orthovanadate). Phosphorylation reactions were per- Immunoblot analysis. Tissues were homogenized in 50 mM Tris-HCl, formed in 10 ~1 of kinase start mix (kinase reaction mix plus 10 &i of pH 7.5, 10 IIIM MgCl,, 1 mM EGTA, 5 mM 2-mercaptoethanol, 0.1 mM [$*P]ATP, 6000 Ciimmol; DuPont NEN, Boston, MA) for 3 min at room phenolmethyl sulfonylfluoride (PMSF; Sigma, St. Louis, MO), 50 Fg/ml temperature. The reaction was stopped by adding 100 ~1 of 100 mM NaCI, aprotinin, 5 mM benzamidine, and 0.1 mM leupeptin (400 ~1) with 50 mM Tris-HCI, pH 7.4, 50 mM EDTA, and 1 mM ATP. Immunopre- glass-glass homogenizers (Micrometric, Tampa, FL). The homogenate cipitates were sedimented, and SDS sample buffer was added after the was centrifuged at 1000 X g to remove debris and then at 100,000 X g for supernatant was aspirated. The samples were boiled and then applied to 30 min in a TL-100 (Beckman, Palo Alto, CA). After SDS-PAGE of 100 SDS-acrvlamide gels. For the immunocomnlex assay. I?*PlATP 16000 pg samples [as measured by the Bradford (1976) method], fractionated Ci/mmolj was used. For immunoblotting, t’he SDS ge&ec&ophoresed proteins were transferred to nitrocellulose (0.45 pm, Bio-Rad). Complete proteins were transferred to nitrocellulose (Bio-Rad, Hercules, CA). transfer was shown by staining with Amido black (Harlow and Lane, Nonspecific binding was blocked by incubating the blot in TBSN buffer 1988). The membrane was blocked in TBSN (25 mM Tris-HCI, pH 8, 130 with 3% BSA for 1 hr at room temperature.
Recommended publications
  • THE FUTURE of SCREENS from James Stanton a Little Bit About Me
    THE FUTURE OF SCREENS From james stanton A little bit about me. Hi I am James (Mckenzie) Stanton Thinker / Designer / Engineer / Director / Executive / Artist / Human / Practitioner / Gardner / Builder / and much more... Born in Essex, United Kingdom and survived a few hair raising moments and learnt digital from the ground up. Ok enough of the pleasantries I have been working in the design field since 1999 from the Falmouth School of Art and onwards to the RCA, and many companies. Ok. less about me and more about what I have seen… Today we are going to cover - SCREENS CONCEPTS - DIGITAL TRANSFORMATION - WHY ASSETS LIBRARIES - CODE LIBRARIES - COST EFFECTIVE SOLUTION FOR IMPLEMENTATION I know, I know, I know. That's all good and well, but what does this all mean to a company like mine? We are about to see a massive change in consumer behavior so let's get ready. DIGITAL TRANSFORMATION AS A USP Getting this correct will change your company forever. DIGITAL TRANSFORMATION USP-01 Digital transformation (DT) – the use of technology to radically improve performance or reach of enterprises – is becoming a hot topic for companies across the globe. VERY DIGITAL CHANGING NOT VERY DIGITAL DIGITAL TRANSFORMATION USP-02 Companies face common pressures from customers, employees and competitors to begin or speed up their digital transformation. However they are transforming at different paces with different results. VERY DIGITAL CHANGING NOT VERY DIGITAL DIGITAL TRANSFORMATION USP-03 Successful digital transformation comes not from implementing new technologies but from transforming your organisation to take advantage of the possibilities that new technologies provide.
    [Show full text]
  • Overview: * Conclusion Modules and Libraries Modern Perl Techniques
    Modern Perl Techniques to Build Distributed Web 2.0 Applications. Presented By: Matt Burns [email protected] * Conclusion Moose just makes things easier. Joose is just like moose but in javascript land. jQuery and Seamstress allow us to be free of clunky template languages. Customized Web Apps spun up on the fly that are stateful are super neato. CPAN modules make concurrent distributed web apps/service possible and straight-forward. Configuration UDC Joose, jQuery Communication Event Distributed Demultiplexing WDC Continuity, Seamstess Computing Dimensions Concurrency Moose, Coro, AnyEvent EDC Service Ideas Behind This: 1) Owning stock and trading options on that will beat owning stock alone. 2) The Web Browser is the new operating system. KiokuDB RDC 3) Distributed parallel programming allows us the ability to tackle very complicated problems. 4) Explore the ideas behind the "Modern Perl" movement. 5) Explore the benefits of the Moose Joose relationship. 6) Instead of templating languages HTML/XML/etc operate directly on the dom. 7) How to enable an ad-hoc system of services to be coordinated into runtime alliances to solve business processes. Distributed Business Component UDC WDC EDC RDC Messages Events Overview: *** Distributed Paradigm Friendly Joose, jQuery Perl, CPAN Dom About how simple(maybe even easy) it is to build a simple distributed application stack with these off the self of CPAN Component Execution Environment The decrease in the impedence mismatch between objects in perl land and objects in Javascript land. Serializing perl/js objects and marshelling them back and forth from the client and server and between server and server. When we think distributed apps there are often many servers working with the client that hosts the user level component of these distributed apps in a piece of dom tied to a Joose object.
    [Show full text]
  • Therapeutic Targeting of the IGF Axis
    cells Review Therapeutic Targeting of the IGF Axis Eliot Osher and Valentine M. Macaulay * Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK * Correspondence: [email protected]; Tel.: +44-1865617337 Received: 8 July 2019; Accepted: 9 August 2019; Published: 14 August 2019 Abstract: The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging. Keywords: IGF; type 1 IGF receptor; IGF-1R; cancer; acromegaly; ophthalmopathy; IGF inhibitor 1. Introduction Insulin like growth factors (IGFs) are small (~7.5 kDa) ligands that play a critical role in many biological processes including proliferation and protection from apoptosis and normal somatic growth and development [1]. IGFs are members of a ligand family that includes insulin, a dipeptide comprised of A and B chains linked via two disulfide bonds, with a third disulfide linkage within the A chain.
    [Show full text]
  • Co-Targeting HER2/Erbb2 and Insulin-Like Growth Factor-1
    Signature: Med Sci Monit, 2002; 8(12): BR521-526 WWW.MEDSCIMONIT.COM PMID: 12503030 Basic Research Received: 2002.11.08 Accepted: 2002.11.20 Co-targeting HER2/ErbB2 and insulin-like growth BR Published: 2002.12.27 factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells Authors’ Contribution: A Study Design abcdef b AG B Data Collection Anne Camirand , Yuhong Lu , Michael Pollak C Statistical Analysis D Data Interpretation Department of Oncology, McGill University, Montréal, QC, Canada E Manuscript Preparation F Literature Search Source of support: Streams of Excellence program of the Canadian Breast Cancer Research Institute. G Funds Collection Summary Background: The humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin®) is useful in the treatment of ErbB2-overexpressing breast cancers, but its efficiency is limited because devel- opment of resistance is common. In order to study the possibility of improving the efficacy of therapies directed against HER2/erbB2, we investigated the effects of co-targeting this recep- tor and the insulin-like growth factor 1 receptor (IGF-1R), a widely-expressed protein tyro- sine kinase with important roles in suppression of apoptosis and stimulation of proliferation. Material/Methods: The experimental strategy involved combining trastuzumab treatment and reduction of IGF- 1R signaling through incremental heat-induced expression of the dominant-negative IGF-1 receptor 486/STOP under the control of the heat-sensitive Drosophila HSP70 promoter, in HER2/erbB2-overexpressing MCF7her18 breast cancer cells. Results: Isobologram analysis of combinatorial treatment data revealed a strong synergistic interaction between trastuzumab treatment and the induction of the dominant-negative IGF-1R expres- sion, resulting in potentiation of growth inhibition in transfected cancer cells.
    [Show full text]
  • Development and Preclinical Evaluation of Cixutumumab Drug
    www.nature.com/scientificreports OPEN Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF‑1R) positive cancer Viswas Raja Solomon1, Elahe Alizadeh1, Wendy Bernhard2, Amal Makhlouf1,3, Siddesh V. Hartimath1, Wayne Hill2, Ayman El‑Sayed2, Kris Barreto2, Clarence Ronald Geyer 2 & Humphrey Fonge1,4* Overexpression of insulin growth factor receptor type 1 (IGF‑1R) is observed in many cancers. Antibody drug conjugates (ADCs) with PEGylated maytansine (PEG6‑DM1) show promise in vitro. We developed PEG6‑DM1 ADCs with low and high drug to antibody ratios (DAR) using an anti‑ IGF‑1R antibody cixutumumab (IMC‑A12). Conjugates with low (cixutumumab‑PEG6‑DM1‑Low) and high (cixutumumab‑PEG6‑DM1‑High) DAR as 3.4 and 7.2, respectively, were generated. QC was performed by UV spectrophotometry, HPLC, bioanalyzer, and biolayer‑interferometry. We compared the in vitro binding and internalization rates of the ADCs in IGF‑1R‑positive MCF‑7/Her18 cells. We radiolabeled the ADCs with 111In and used microSPECT/CT imaging and ex vivo biodistribution to understand their in vivo behavior in MCF‑7/Her18 xenograft mice. The therapeutic potential of the ADC was studied in vitro and in mouse xenograft. Internalization rates of all ADCs was high and increased over 48 h and EC50 was in the low nanomolar range. MicroSPECT/CT imaging and ex vivo 111 biodistribution showed signifcantly lower tumor uptake of In‑cixutumumab‑PEG6‑DM1‑High 111 111 compared to In‑cixutumumab‑PEG6‑DM1‑Low and In‑cixutumumab. Cixutumumab‑PEG6‑DM1‑ Low signifcantly prolonged the survival of mice bearing MCF‑7/Her18 xenograft compared with cixutumumab, cixutumumab‑PEG6‑DM1‑High, or the PBS control group.
    [Show full text]
  • Interactions Between EGF and the IGF-1 Receptor in Mediating Hgly2-GLP-2-Induced Proliferation in the Murine Small Intestine
    Interactions Between EGF and the IGF-1 Receptor in Mediating hGly2-GLP-2-Induced Proliferation in the Murine Small Intestine by Zivit Fesler A thesis submitted in conformity with the requirements for the degree of Master’s of Science Department of Physiology University of Toronto © Copyright by Zivit Fesler 2019 Interactions Between EGF and the IGF-1 Receptor in Mediating hGly2-GLP-2-Induced Proliferation in the Murine Small Intestine Zivit Fesler Master’s of Science Department of Physiology University of Toronto 2019 Abstract Glucagon-like peptide-2 (GLP-2) is an intestinotrophic hormone that promotes intestinal proliferation through downstream mediators. Two known mediators are insulin-like growth factor-1 (IGF-1) and epidermal growth factor (EGF), both essential for the proliferative effect of GLP-2. I hypothesized that pre- and/or co-EGF enhances IGF-1-mediated GLP-2-induced proliferation in the murine model. Chronic combination treatment of EGF and GLP-2 increased intestinal growth in C57Bl/6 mice compared to vehicle, GLP-2 and respective EGF treatments. Treatment of pre-EGF+co-EGF+GLP-2 in intestinal epithelial IGF-1 receptor (IGF-1R) knockout mice restored intestinal growth despite the lack of a receptor essential for GLP-2 signaling. Finally, IGF-1 treatment in organoids did not have an additive effect to EGF on proliferation, but managed to replace EGF as an essential growth factor in the media to maintain normal proliferation. Together, these data suggest that exogenous EGF is an essential mediator for GLP-2 that can supersede the missing signaling pathway of IGF-1R. ii Acknowledgments Graduate school has been an important learning and growing environment for me.
    [Show full text]
  • Insulin-Like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells
    Research Article Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells Rita Nahta,1 Linda X.H. Yuan,1 Bing Zhang,1 Ryuji Kobayashi,2 and Francisco J. Esteva1,3,4 Departments of 1Breast Medical Oncology, 2Molecular Pathology, and 3Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center and 4The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas Abstract against the extracellular domain of the human epidermal growth The majority of breast cancer patients who achieve an factor (EGF) receptor 2 (HER-2) tyrosine kinase receptor (2). initial therapeutic response to the human epidermal growth Clinical studies established that trastuzumab is active against factor receptor 2 (HER-2)–targeted antibody trastuzumab HER-2-overexpressing metastatic breast cancers (3–5), leading to will show disease progression within 1 year. We previously its approval in 1998 by the U.S. Food and Drug Administration. reported the characterization of SKBR3-derived trastuzumab- However, the objective response rates to trastuzumab mono- resistant pools. In the current study, we show that HER-2 therapy are quite low, ranging from 12% to 34% for a median interacts with insulin-like growth factor-I receptor (IGF-IR) duration of 9 months (4, 5). The majority of patients who achieve an initial response to trastuzumab-based therapy acquire uniquely in these resistant cells and not in the parental trastuzumab-sensitive cells. The occurrence of cross talk resistance within 1 year of treatment initiation (6, 7). Elucidating between IGF-IR and HER-2 exclusively in resistant cells is the mechanisms by which tumors escape the cytotoxic properties evidenced by the IGF-I stimulation resulting in increased of trastuzumab is critical to improving the survival of metastatic phosphorylation of HER-2 in resistant cells, but not in breast cancer patients whose tumors overexpress HER-2.
    [Show full text]
  • Novel Pathways Promoting Thyroid Tumourigenesis and Growth
    NOVEL PATHWAYS PROMOTING THYROID TUMOURIGENESIS AND GROWTH By Gregory Douglas Lewy A thesis presented to the College of Medical and Dental Sciences at the University of Birmingham for the Degree of Doctor of Philosophy Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine March 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. SUMMARY Thyroid cancers are the most common endocrine malignancies and their incidence continues to rise. Over-expression of the human pituitary tumor transforming gene (hPTTG) in thyroid carcinomas is a prognostic indicator of tumour recurrence. hPTTG is multifunctional with roles in mitotic control, DNA repair, genetic instability, cell transformation and apoptosis. Importantly, hPTTG transactivates expression of growth factors implicated in proliferation and angiogenesis, and represses the sodium iodide symporter (NIS), which is essential to radioiodine treatments in thyroid cancer. hPTTG interacts with a binding factor (PBF) which is an independent transforming gene and also represses iodine uptake. Work described in this thesis provides evidence for the existence of thyroidal autocrine regulatory pathways involving hPTTG and growth factors in vitro. We directly investigated the role of hPTTG in thyroid tumourigenesis through the generation and characterisation of a murine transgenic model with thyroid-targeted hPTTG over-expression (hPTTG-Tg mice).
    [Show full text]
  • Co-Targeting IGF-1R and C-Kit: Synergistic Inhibition of Proliferation and Induction of Apoptosis in H 209 Small Cell Lung Cancer Cells
    British Journal of Cancer (2004) 90, 1825 – 1829 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com Short Communication Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells 1 *,1 A Camirand and M Pollak 1Lady Davis Institute for Medical Research and Department of Oncology, McGill University, Montre´al, QC, Canada Most small cell lung cancers (SCLC) coexpress the c-kit protein tyrosine receptor kinase and its ligand stem cell factor, resulting in an autocrine loop. As SCLC growth is also driven by insulin-like growth factor-1 receptor (IGF-1R) signalling, tyrphostins AG 1024 and 1296 (inhibitors of IGF-1R and c-kit activity, respectively) were used to co-target these receptors in H 209 SCLC cells. Combination treatment caused synergy in proliferation inhibition and in apoptosis induction, and also enhanced reduction in phosphorylation of Erk1/Erk2, suggesting that co-targeting IGF-1R and c-kit in SCLC may be more effective than single-agent therapies. British Journal of Cancer (2004) 90, 1825 – 1829. doi:10.1038/sj.bjc.6601682 www.bjcancer.com Published online 20 April 2004 & 2004 Cancer Research UK Keywords: IGF-1R; c-kit; co-targeting; small cell lung cancer; synergy The signalling activity of receptor protein tyrosine kinases (PTKs) AG 1296 (which inhibits c-kit and PDGFR (Kovalenko et al,1994)) tightly controls crucial cellular processes such as apoptosis, and indolinones SU 5416 and SU6597 (inhibitors of c-kit and related differentiation and proliferation, and it is therefore not surprising kinases (Krystal et al, 2001)) reduce SCLC proliferation in vitro that deregulation of these molecules often leads to neoplastic (Krystal et al, 1997, 2000, 2001; Wang et al,2000;Kijimaet al, 2002).
    [Show full text]
  • Development and Diagnostic Application of a Novel Quantitative
    Development and Diagnostic Application of a Novel Quantitative Test for Determination and Characterization of Autoantibodies against Insulin-like Growth Factor 1 Receptor Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by TIM WELSINK from Düsseldorf 2014 Entwicklung und diagnostische Anwendung eines neuen Nachweisverfahrens zur Bestimmung und Charakterisierung von Autoantikörpern gegen den Insulin-like Growth Factor 1 Rezeptor Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.) eingereicht im Fachbereich Biologie, Chemie, Pharmazie der Freien Universität Berlin vorgelegt von TIM WELSINK aus Düsseldorf 2014 This dissertation was prepared from 2010 to 2014 at the Institute for Experimental Endocrinology at Charité - Universitätsmedizin Berlin and has been supervised by Prof. Dr. Lutz Schomburg. Professor Dr. Markus Wahl has been the supervisor at the Institute for Chemistry and Biochemistry at Freie Universität Berlin. Angefertigt wurde diese Dissertation in den Jahren 2010 bis 2014 am Institut für Experimentelle Endokrinologie der Charité - Universitätsmedizin Berlin unter der Leitung von Prof. Dr. Lutz Schomburg. Betreut wurde diese Dissertation am Institut für Chemie und Biochemie der Freien Universität Berlin von Prof. Dr. Markus Wahl. 1. Gutachter (first referee): Prof. Dr. Lutz Schomburg 2. Gutachter (second referee): Prof. Dr. Markus Wahl Disputation am (disputation date) 13. April 2015 Summary / Zusammenfassung Summary / Zusammenfassung Summary Autoantibodies (aAb) are characteristic for autoimmune diseases. Specific aAb are often found both in diseased and apparently healthy individuals and may precede pathological symptoms. The contribution of thyrotropin receptor (TSHR) stimulating aAb to the progression of Graves´ Orbitopathy (GO) is widely accepted.
    [Show full text]
  • 2018/19 Steamboat Press Kit
    2018/19 Steamboat Press Kit TABLE OF CONTENTS What’s new this winter at Steamboat ............................................................... Pages 2-3 New ownership, additional nonstop flights, mountain coaster, gondola upgrades Expanded winter air program ........................................................................... Pages 4-5 Fly nonstop into Steamboat from 15 major U.S. airports. New this year: Boston, Fort Lauderdale, and Long Beach, California. Winter Olympic tradition ................................................................................ Pages 6-11 Steamboat has produced 96 winter Olympians, more than any other town in North America. Champagne Powder® snow ............................................................................ Pages 12-14 Family programs ............................................................................................. Pages 15-17 Mountain facts and statistics ......................................................................... Pages 18-21 History of Steamboat ...................................................................................... Pages 22-30 Events calendar .............................................................................................. Pages 31-34 Cowboy Downhill ............................................................................................ Pages 35-36 Night skiing and snowboarding ..................................................................... Pages 37-38 On-mountain dining and Steamboat’s top restaurants ..............................
    [Show full text]
  • Estrogen Receptor Regulates Insulin-Like Growth Factor-I Receptor Gene Expression in Breast Tumor Cells: Involvement of Transcription Factor Sp1
    605 Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1 Sharon Maor, Doris Mayer1, Ronit I Yarden2, Adrian V Lee3, Rive Sarfstein, Haim Werner and Moshe Z Papa4 Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel 1Group on Hormones and Signal Transduction, German Cancer Research Center, Heidelberg D-69120, Germany 2Laboratory of Genomic Applications, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel 3Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA 4Department of Oncological Surgery, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel (Requests for offprints should be addressed to H Werner; Email: [email protected]) Abstract The insulin-like growth factors, IGF-I and IGF-II are a familyof along with the Sp1-family-binding inhibitor Mithramycin A. mitogenic polypeptides with important roles in growth and The results obtained indicate that basal IGF-IR promoter differentiation. The biological actions of the IGFs are mediated activity was 5.8-fold higher in MCF-7 than in C4 cells. Estradiol by the IGF-I receptor (IGF-IR), a cell-surface tyrosine kinase, treatment significantly activated the IGF-IR promoter in whose activation by serum IGF-I seems to be a key step in breast MCF-7, but not in C4 cells. Furthermore, the estrogen cancer initiation. Evidence accumulated indicates that estrogens responsive region in the IGF-IR promoter was mapped to a stimulate the expression and activity of IGF axis components. GC-rich sequence located between nucleotides K40 and The aim of our study was to examine the transcriptional K188 in the 50 flanking region.
    [Show full text]